Global Infantile Spasms Therapeutics Market 2017-2021
About Infantile Spasms Therapeutics
An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox–Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.
Technavio’s analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Infantile Spasms Therapeutics Market 2017-2021
Technavio recognizes the following companies as the key players in the global infantile spasms therapeutics market: H. Lundbeck, Mallinckrodt Pharmaceuticals, and INSYS Therapeutics
Other Prominent Vendors in the market are: Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, and Valerion Therapeutics
Commenting on the report, an analyst from Technavio’s team said: “The new trend observed in the infantile spasms market is the development of seizure alert devices that detects the seizure and notifies it to the physician, through alarms, phone calls, or text messages. SmartMonitor has developed a watch, SmartWatch, which should be worn 24 hours a day to detect any seizures. If it detects any seizures, it immediately sends out an alert warning to the caregivers/physicians. The device is now available only in the US. Also, Empatica has developed another smart watch, Embrace, which monitors the physiological stress, arousal, sleep, and physical activity of the individual. Apart from this, a smartphone application EpDetect has been developed, which exploits advanced signal processing to detect seizures. Once a seizure is detected, the application will inform the caregiver about the status of the patient along with the global positioning system (GPS) location. Similarly, BioLert has also developed EpiLert, which is an alert device with GPS and text messaging systems.”
According to the report, special regulatory designations such as fast track designations and orphan drugs designation assigned to the drugs by the US FDA and the EMA help in the faster entry of these drugs into the market. Fast track designations are assigned to the drugs used in the treatment of serious conditions with high unmet need prevailing in the market. Similarly, orphan drug designations are assigned for the drugs used in the treatment of rare diseases. These designations help in the faster approval process for the drugs and help in early entry into the market.
Further, the report states that orphan diseases such as infantile spasms disease have a lower incidence and prevalence rate than other diseases. According to the research studies published in 2015, the disease affected about one in 2,000-4,000 live births and approximately 10,000-20,000 infants were afflicted globally. Limited patient population restricts the clinical trial evaluation of drug candidates under development for the treatment of orphan indications. Drugs tested in these trials also fail to provide statistically significant results, even if they are efficacious and highly safe for consumption. Also, limited enrollment for clinical trials increases the occurrence of post-marketing adverse events. Clinical trials of new drugs and already available drugs also require large treatment populations. Drug manufacturers and researchers are also not able to recover their R&D expenses of the drugs and generate profits because of the limited patient population.
H. Lundbeck, Mallinckrodt Pharmaceuticals, INSYS Therapeutics, Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, Valerion Therapeutics.